This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Edwards-JenaValve deal better for patients, companies argue in post-trial brief

By Wesley Brown ( December 12, 2025, 22:06 GMT | Insight) -- Edwards Lifesciences and JenaValve Technology submitted a post-trial brief Friday, arguing that their transaction is the best way forward for the companies and patients. The companies maintain that the US Federal Trade Commission failed to weigh the anticompetitive effects of the merger against the procompetitive effects or identify harm to any market.Edwards Lifesciences and JenaValve Technology submitted a post-trial brief Friday, arguing that their transaction is the best way forward for the companies and patients....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login